Dexmedetomidine is an a2-adrenergic receptor agonist with an eight-fold greater affinity for the a2-adrenergic receptor than its sister drug clonidine. It is a sedative that is clear, colourless and tasteless and has been used in children for a number of years. Advantages of Dexmedetomidine over other agents used in paediatrics include: ease of administration; reduction in postoperative analgesic requirements; and reduction in postoperative nausea and vomiting (PONV).
Recent Posts
- Editorial: Anesthetic neurotoxicity in developing brains: mechanisms, biomarkers, and therapeutic targets.
- Development of a primate model to evaluate the effects of ketamine and surgical stress on the neonatal brain.
- Sevoflurane anaesthesia induces cognitive impairment in young mice through sequential tau phosphorylation.
- Dexmedetomidine suppresses hippocampal astrocyte pyroptosis in cerebral hypoxic-ischemic neonatal rats by upregulating microRNA-148a-3p to inactivate the STAT/JMJD3 axis.
- miR-34a targets SIRT1 to reduce p53 deacetylation and promote sevoflurane inhalation anesthesia-induced neuronal autophagy and apoptosis in neonatal mice.